Research ArticleClinical Studies
Prognostic Stratification of the IMDC Intermediate Risk Group After Treatment With First-line Molecular-targeted Therapy for Metastatic Renal Cell Carcinoma
KIYOSHI TAKAHARA, RYOSUKE ANDO, KENT KANAO, TOSHIKI ITO, HIDEAKI MIYAKE, MAKOTO SUMITOMO, TAKAHIRO YASUI and RYOICHI SHIROKI
Anticancer Research August 2020, 40 (8) 4395-4400; DOI: https://doi.org/10.21873/anticanres.14443
KIYOSHI TAKAHARA
1Department of Urology, Fujita Health University, School of Medicine, Toyoake, Japan
RYOSUKE ANDO
2Department of Nephrourology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
KENT KANAO
3Department of Uro-Oncology, Saitama Medical University International Medical Center, Hidaka, Japan
TOSHIKI ITO
4Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan
HIDEAKI MIYAKE
4Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan
MAKOTO SUMITOMO
1Department of Urology, Fujita Health University, School of Medicine, Toyoake, Japan
TAKAHIRO YASUI
2Department of Nephrourology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
RYOICHI SHIROKI
1Department of Urology, Fujita Health University, School of Medicine, Toyoake, Japan
In this issue
Prognostic Stratification of the IMDC Intermediate Risk Group After Treatment With First-line Molecular-targeted Therapy for Metastatic Renal Cell Carcinoma
KIYOSHI TAKAHARA, RYOSUKE ANDO, KENT KANAO, TOSHIKI ITO, HIDEAKI MIYAKE, MAKOTO SUMITOMO, TAKAHIRO YASUI, RYOICHI SHIROKI
Anticancer Research Aug 2020, 40 (8) 4395-4400; DOI: 10.21873/anticanres.14443
Prognostic Stratification of the IMDC Intermediate Risk Group After Treatment With First-line Molecular-targeted Therapy for Metastatic Renal Cell Carcinoma
KIYOSHI TAKAHARA, RYOSUKE ANDO, KENT KANAO, TOSHIKI ITO, HIDEAKI MIYAKE, MAKOTO SUMITOMO, TAKAHIRO YASUI, RYOICHI SHIROKI
Anticancer Research Aug 2020, 40 (8) 4395-4400; DOI: 10.21873/anticanres.14443
Jump to section
Related Articles
- No related articles found.